immunohistochemistry breast cancer

Release time ：Dec-25,2024

Immunohistochemistry (IHC) plays a pivotal role in diagnosing breast cancer, aiding physicians in ascertaining the specific protein profiles of tumor cells, which facilitates more precise classification and planning of treatment strategies. Typically, outcomes from IHC tests influence the selection of therapeutic regimens for patients, encompassing surgical interventions, radiotherapy, chemotherapy, and targeted therapies.

The most frequently assessed markers in IHC for breast cancer include the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These markers guide physicians in selecting the most suitable treatment approach. For instance, patients testing positive for ER and PR may be candidates for endocrine therapy, while those with HER2 positivity could derive benefits from anti-HER2 therapies. Beyond these, IHC can also identify additional biomarkers, such as Ki-67—a marker of proliferation—and P53—a tumor suppressor protein—the results of which can further inform treatment decisions.

Understanding one's IHC test results is crucial for breast cancer patients, as these results directly influence the choice of treatment plan. Consequently, it is imperative for patients to engage in thorough discussions with their healthcare providers prior to initiating treatment to comprehend their test outcomes and how these may impact their treatment options. Patients should also adhere to their physician's recommendations, undergo treatment promptly, and schedule regular follow-ups to ensure timely adjustments to their treatment protocols as needed.